Related to the synthetic lethal DNA damage elicited in homologous recombination-defective cancer cells, many clinical PARPi can trap PARP1 and PARP2 on DNA as part of their anticancer mechanism of action (1, 33). The gene discussed is PARP1; the disease is cancer.